Result of AGM

Oxford Biomedica PLC
23 June 2023
 

 

 

 

Oxford Biomedica

Result of Annual General Meeting

 

Oxford, UK - 23 June 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 23 June 2023 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxb.com  

 

Copies of the document setting out the above resolutions passed at the 2023 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

On the Record Date (21 June 2023) there were 96,521,209 ordinary shares of 50 pence each in issue, each carrying one vote per share.

 

 

 

 

 

 

 

Resolution

 

Votes

For (incl. votes at the Chairman's discretion)

 

 

  

% of votes cast

 

Votes

Against

 

 


% of votes cast

 

Votes

Withheld*

 

Total

votes cast

Result

 

 

 

 

 

 

 

 

 

 

Ordinary resolutions
















1

 

To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022.

73,060,750

100.00%

629

0.00%

146,857

73,061,379

PASS

2

 

 

 

 

 

 

To receive the Directors' Remuneration Report and the Report of the Auditor on the Remuneration Report for the year ended 31 December 2022.

51,080,127

79.93%

12,826,613

20.07%

9,301,496

63,906,740

PASS

3

 

To appoint Dr. Frank Mathias as a Director.

73,062,102

99.81%

137,244

0.19%

8,890

73,199,346

PASS

4

 

To appoint Leone Patterson as a Director.

72,892,590

99.58%

307,356

0.42%

8,290

73,199,946

PASS

5

 

To reappoint Dr. Roch Doliveux as a Director.

67,536,075

92.26%

5,662,468

7.74%

9,693

73,198,543

PASS

6

To reappoint Professor Dame Kay Davies as a Director.

66,057,059

90.24%

7,141,705

9.76%

9,472

73,198,764

PASS

7

 

To reappoint Stuart Paynter as a Director.

72,551,391

99.11%

649,338

0.89%

7,507

73,200,729

PASS

8

 

To reappoint Stuart Henderson as a Director.

66,051,339

90.25%

7,139,682

9.75%

17,215

73,191,021

PASS

9

 

To reappoint Dr. Heather Preston as a Director

64,485,621

88.10%

8,713,178

11.90%

9,437

73,198,799

PASS

10

 

To reappoint Robert Ghenchev as a Director.

73,059,336

99.81%

140,259

0.19%

8,641

73,199,595

PASS

11

 

To reappoint Dr. Michael Hayden as a Director.

67,826,937

92.66%

5,371,827

7.34%

9,472

73,198,764

PASS

12

 

To reappoint Catherine Moukheibir as a Director.

68,240,515

93.22%

4,959,431

6.78%

8,290

73,199,946

PASS

13

 

To reappoint Namrata P. Patel as a Director.

73,140,356

99.92%

59,590

0.08%

8,290

73,199,946

PASS

14

 

 

To appoint PriceWaterhouseCoopers LLP as auditor.

73,193,707

99.99%

7,290

0.01%

7,239

73,200,997

PASS

15

 

To authorise the Directors to agree the remuneration of the auditor.

73,195,908

99.99%

4,776

0.01%

7,552

73,200,684

PASS

16

To authorise the Directors to allot shares.

70,498,713

96.31%

2,702,643

3.69%

6,880

73,201,356

PASS

 

 

Special resolutions







17

 

 

To authorise the Directors to disapply pre-emption rights.

72,202,544

98.64%

996,404

1.36%

9,288

73,198,948

PASS

18

 

 

 

 

 

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.

70,474,362

96.28%

2,721,812

3.72%

12,062

73,196,174

PASS

19

 

 

 

 

 

To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

71,049,162

97.06%

2,150,941

2.94%

8,133

73,200,103

PASS

 

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

 

In addition, further to the announcement by the Company in January, Dr. Siyamak Rasty has stepped down from the Company's Board of Directors with effect from the conclusion of today's AGM.

 

The Board recognises that, whilst resolution 2 was passed with a clear majority at almost 80%, there was also a significant vote against this resolution. The Board will seek to engage with those shareholders who voted against this resolution and it is anticipated that a revised remuneration policy will be presented to shareholders for their approval at the Company's AGM in 2024. In accordance with the UK Corporate Governance Code, an update on the views received from shareholders and details of any further actions taken by the Company will be published no later than 23 December 2023 by way of Stock Exchange Announcement. A summary will also be published in the 2023 Annual Report and Accounts.

 

 

 

-Ends-

 

 

           

Enquiries:       

 

 

Oxford Biomedica plc:

 

Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488/ E: ir@oxb.com

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E: ir@oxb.com

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

Mary-Jane Elliott / Matthew Neal / Davide Salvi

 

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings